CJC-1295 2mg 69 € + Shipping ^Sale

CJC-1295 is a growth-hormone-releasing hormone (GHRH) analog based on a tetrasubstituted hGRF(1-29) backbone. This product is the without-DAC form (Modified GRF 1-29): it lacks the Drug Affinity Complex, giving a short half-life intended to mimic natural pulsatile release. It is studied as a GHRH-receptor agonist driving GH gene transcription in pituitary somatotrophs. Supplied as a lyophilized research-grade peptide for in vitro and preclinical laboratory investigation only.

Investigational directions enabled by the published mechanism — not therapeutic claims.

• ◆Prolonged GH release vs native GHRH or short-acting analogues
• ◆Sustained IGF-1 elevation for tissue-growth and repair research
• ◆Muscle & bone studies: growth, body weight and bone length in GHRH-knockout models
• ◆Metabolic & longevity: GH/IGF-1-axis modulation in fat-metabolism and healthy-aging contexts

In published models, the tetrasubstituted hGRF(1-29) backbone agonizes the GHRH receptor on somatotrophs, signaling through Gαs → cAMP → PKA → CREB to drive GH gene transcription and somatotroph growth. The four substitutions resist DPP-IV degradation, and sustained receptor stimulation preserves pulsatile GH rather than a tonic elevation.

Key literature: Jetté et al., 2005 · Teichman et al., 2006 · Alba et al., 2006 · Sackmann-Sala et al., 2009.

Evidence note: the pivotal human RCT figures (GH ↑2–10×; IGF-1 ↑1.5–3× for 9–11 days; Teichman 2006) are for the DAC-modified form; data for this without-DAC form is limited to Phase-1.